NDAIMPLANTATIONIMPLANT
Approved
Jul 2006
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
NEXPLANON (etonogestrel) by Merck & Co. is ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium. Approved for contraception. First approved in 2006.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXPLANON is a subdermal progestin implant containing etonogestrel, approved in 2006 for contraception. It prevents pregnancy through suppression of ovulation, increased cervical mucus viscosity, and endometrial alterations. The 3-year implant is inserted subdermally and provides continuous hormone delivery.
$0.402MPart D
Peak4.2 years to LOEProduct is at peak lifecycle with stable utilization; Merck maintains a dedicated commercial infrastructure, though team size optimization occurs as patent expiration approaches.
Mechanism of Action
ovulation, increased viscosity of the cervical mucus, and alterations in the endometrium.
Pharmacologic Class:
Progestin
Indications (1)
Clinical Trials (20)
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Started Jul 2024
34 enrolled
Primary Ovarian InsufficiencyHypogonadotropic HypogonadismHormone Replacement Therapy
Barriers to Referring Adolescent Women for Etonogestrel Implant.
Started Sep 2023
0Contraceptive Usage
Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring
Started Jul 2023
36 enrolled
Healthy WomenFemaleContraception
Etonogestrel Implant as Emergency Contraception
Started Apr 2022
12 enrolled
Contraception
Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™
Started Feb 2021
51 enrolled
Birth ControlContraceptionImplant+2 more
Worked on NEXPLANON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.